Galenica Confirms 2026 Adjusted EBIT Growth Outlook of 6%-8%
- Galenica confirmed its 2026 outlook for sales growth of 5%-7% and adjusted EBIT growth of 6%-8%.
- The dividend is expected to at least match the previous year's level.
- Nine-month sales rose 5.7% to CHF 3.17 billion, driven by pharmacies, home care and Diagnostics integration.
- Wholesale growth is expected to accelerate in the fourth quarter following completion of the ERP migration.
- Temporary product-range restrictions during the migration slowed third-quarter wholesale growth; nine-month wholesale sales rose 2.8% to CHF 2.44 billion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galenica AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2419592_en) on October 22, 2026, and is solely responsible for the information contained therein.